| *123590 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYSTALLIN, ALPHA-B; CRYAB | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative titles; symbols | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYSTALLIN, ALPHA-2; CRYA2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HGNC Approved Gene Symbol: CRYAB | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cytogenetic location: 11q23.1 Genomic coordinates (GRCh37): 11:111,779,349 - 111,782,472 (from NCBI) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gene Phenotype Relationships | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TEXT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Description | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The crystallins compose approximately 90% of the soluble protein of the vertebrate eye lens and include 3 major families of ubiquitously expressed crystallins: alpha (e.g., CRYAA; 123580), beta (e.g., CRYBA1; 123610), and gamma (e.g., CRYGA; 123660). Alpha-B-crystallin is a member of the small heat-shock protein family (Dubin et al., 1990). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cloning | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dubin et al. (1990) presented the complete nucleotide sequence of the human CRYAB gene, which encodes a 175-amino acid protein with a molecular mass of 20 kD. In the mouse, Dubin et al. (1989) found that the Cryab gene is expressed in the lens, heart, skeletal muscle, kidney, and lung. In the rat, Iwaki et al. (1990) found Cryab expression in lens, iris, heart, skeletal muscle, certain regions of the kidney, Schwann cells of peripheral nerves, glia in the central nervous system, and decidual cells of the placenta. By functional analysis of a CRYAB promoter fragment fused to the bacterial chloramphenicol acetyltransferase (CAT) gene, Dubin et al. (1990) found that the fragment contains regulatory elements that function predominantly, but not exclusively, in lens. Although alpha-B-crystallin had been reported to accumulate in brain cells in Alexander disease (203450) (Iwaki et al., 1989), Dubin et al. (1990) found that the promoter fragment was insufficient to promote transcription in a glial cell line that synthesizes high levels of the endogenous CRYAB gene product. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gene Function | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Van Noort et al. (1995) examined proliferative responses of human peripheral blood T cells to the complete collection of myelin proteins, including alpha-B-crystallin. They found that alpha-B-crystallin was a highly immunogenic protein to which T cells from multiple sclerosis (MS; 126200) patients and from healthy controls showed dominant responses. Immunohistochemical examination of MS lesions revealed the presence of oligodendrocytes and astrocytes with raised CRYA2 expression, which was not found in unaffected myelin, suggesting that the CRYA2 protein may be an autoantigen in MS. The authors noted that alpha-B-crystallin had been detected in brains of patients with other neurologic diseases, including Alzheimer (104300), Parkinson (168600, 168601), Pick (172700), and Huntington (143100) diseases. Steinman (1995) discussed the significance of the immune reaction against alpha-B-crystallin in the pathology of MS. The alpha-crystallin subunits alpha-A and alpha-B each can form an oligomer by itself or with the other. Fu and Liang (2002) used a 2-hybrid system to study heterogeneous interactions among lens crystallins of different classes. They found interactions between alpha-A- (or alpha-B-) and beta-B2- or gamma-C- (123680)-crystallins, but the intensity of interaction was one-third that of alpha-A-alpha-B interactions. HSP27 (602195), a member of the small heat-shock protein family, showed similar interaction properties with alpha-B-crystallin. Experiments with N- and C-terminal domain-truncated mutants demonstrated that both N- and C-terminal domains were important in alpha-A-crystallin self-interaction, but that only the C-terminal domain was important in alpha-B-crystallin self-interaction. Cataractogenesis (development of lens opacity) is believed to be a consequence of accumulation of insoluble aggregates and gross-linked products of alpha-, beta-, and gamma-crystallins. The insolubilization of crystallins is thought to be initiated by posttranslational modifications that change their structural and functional properties. Srivastava and Srivastava (2003) showed that the asparagine-146 residue (N146) of human alpha-B-crystallin undergoes in vivo deamidation, and several fragments containing this modification were found in both water-soluble and -insoluble protein fractions of normal and cataractous human lenses. Gupta and Srivastava (2004) showed that deamidation of N146 but not of N78 of CRYAB had profound effects on the structural and functional properties of alpha-B-crystallin. By immunohistochemical analysis, Moyano et al. (2006) found that CRYAB was expressed in 18 (45%) of 40 basal-like breast tumors and predicted poor survival of breast cancer patients independently of other prognostic markers. Overexpression of CRYAB transformed immortalized human mammary epithelial cells (MECs) and conferred neoplastic-like changes, which were suppressed by MEK (see MAP2K1; 176872) inhibitors. Immortalized human MECs overexpressing CRYAB formed invasive mammary carcinomas in nude mice that recapitulated aspects of human basal-like breast tumors. Wang et al. (2005) found that in SOD1 (147450)-mutant mouse cells alpha-B-crystallin suppressed aggregation of mutant SOD1 in somatodendritic compartments. In vivo, alpha-B-crystallin immunoreactivity was most abundant in oligodendrocytes and upregulated in astrocytes of symptomatic mice; neither of these cell types accumulated mutant SOD1 immunoreactivity. Wang et al. (2005) suggested that damage to motor neuron cell bodies and dendrites within the spinal cord may be sufficient to induce motor neuron disease, and that activities of chaperones may modulate the cellular specificity of mutant SOD1 accumulation. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gene Structure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dubin et al. (1990) determined that the CRYAB gene contains 3 exons. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mapping | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| By use of a CRYA2 genomic probe in connection with mouse-human somatic cell hybrid DNA, Ngo et al. (1989) assigned the gene to chromosome 11; by in situ hybridization, they regionalized the locus to 11q22.3-q23.1. By study of a panel of human/rodent hybrid cell lines using a probe consisting of the third exon of the hamster alpha-B-crystallin gene, Brakenhoff et al. (1990) assigned the CRYA2 gene to chromosome 11. Using cell hybrids containing translocated and/or partially deleted human chromosome 11, they localized the CRYA2 gene further to 11q12-q23. Jeanpierre et al. (1993) showed that the CRYA2 gene lies proximal to the 11q23.2 breakpoint defined by the constitutional t(11;22) and distal to the 11q22.1 breakpoint of a constitutional interstitial deletion. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Genetics | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Myofibrillar Myopathy, Alpha-B Crystallin-Related In affected members of a family with an autosomal dominant myofibrillar myopathy (608810) reported by Fardeau et al. (1978), Vicart et al. (1998) identified a heterozygous mutation in the CRYAB gene (123590.0001). In 2 unrelated patients with myofibrillar myopathy, Selcen and Engel (2003) identified 2 different heterozygous mutations in the CRYAB gene (123590.0003; 123590.0004). Expression studies of both mutations were consistent with a dominant-negative effect. By in vitro experiments using different CRYAB mutants, Hayes et al. (2008) found that the C-terminal extension was important for oligomerization. The Q151X mutation (123590.0004) decreased oligomerization and even increased some chaperone activities, but it also significantly destabilized the protein and caused self-aggregation. The 450delA (123590.0002) and 464delCT (123590.0003) mutants could only be refolded and assayed as a complex with wildtype CRYAB. Hayes et al. (2008) concluded that mutations in the C-terminal extension destabilize the protein and increase its tendency to self-aggregate. It is this tendency, rather than a loss of chaperone activity, that is the major pathogenic factor. Fatal Infantile Hypertonic Myofibrillar Myopathy In 8 patients with fatal infantile hypertonic myofibrillar myopathy (613869), Del Bigio et al. (2011) identified the same homozygous 1-bp deletion in the CRYAB gene (60delC; 123590.0005). All patients were Canadian aboriginals of Cree descent, consistent with a founder effect. The phenotype was characterized by onset in the first weeks of life of rapidly progressive muscular rigidity of the trunk and limbs associated with increasing respiratory difficulty resulting in death before age 3 years. Cataract In a 4-generation family of English descent with autosomal dominant congenital posterior polar cataracts (CTPP2; 613763), Berry et al. (2001) identified a deletion mutation in the CRYAB gene (123590.0002). Fu and Liang (2003) studied the effect of crystallin gene mutations that result in congenital cataract on protein-protein interactions. Interactions between mutated crystallins alpha-A (R116C; 123580.0001), alpha-B (R120G; 123590.0001), and gamma-C (T5P; 123680.0001) and the corresponding wildtype proteins, as well as with wildtype beta-B2-crystallin (123620) and HSP27, were analyzed in a mammalian cell 2-hybrid system. For mutated alpha-A-crystallin, interactions with wildtype beta-B2-crystallin and gamma-C-crystallin decreased and those with wildtype alpha-B-crystallin and HSP27 increased. For mutated alpha-B-crystallin, interactions with wildtype alpha-A-crystallin and alpha-B-crystallin decreased, but those with wildtype beta-B2-crystallin and gamma-C-crystallin increased slightly. For mutated gamma-C-crystallin, most of the interactions were decreased. The results indicated that crystallin mutations involved in congenital cataracts altered protein-protein interactions, which might contribute to decreased protein solubility and formation of cataract. Multiple Sclerosis Van Veen et al. (2003) presented evidence suggesting that polymorphisms in the promoter region of the CRYAB gene may influence the clinical phenotype of multiple sclerosis (126200). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Animal Model | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alpha-B-crystallin is the most abundant gene transcript present in early active multiple sclerosis lesions, whereas such transcripts are absent in normal brain tissue. This crystallin has antiapoptotic and neuroprotective functions. CRYAB is the major target of CD4+ T cell immunity to the myelin sheath from multiple sclerosis brain. Ousman et al. (2007) demonstrated that CRYAB is a potent negative regulator acting as a brake on several inflammatory pathways in both the immune system and central nervous system. Cryab-null mice showed worse experimental autoimmune encephalomyelitis at the acute and progressive phases, with higher Th1 and Th17 cytokine secretion from T cells and macrophages, and more intense central nervous system (CNS) inflammation, compared with their wildtype counterparts. Furthermore, Cryab-null astrocytes showed more cleaved caspase-3 (600636) and more TUNEL staining, indicating an antiapoptotic function of Cryab. Alexander disease is a primary disorder of astrocytes caused by dominant mutations in the gene for glial fibrillary acidic protein (GFAP; 137780). These mutations lead to protein aggregation and formation of Rosenthal fibers, complex astrocytic inclusions that contain GFAP, vimentin (VIM; 193060), plectin (PLEC1; 601282), ubiquitin (UBB; 191339), Hsp27, and CRYAB. CRYAB regulates GFAP assembly, and elevation of CRYAB is a consistent feature of Alexander disease; however, its role in Rosenthal fibers and disease pathology is not known. In a mouse model of Alexander disease, Hagemann et al. (2009) showed that loss of Cryab resulted in increased mortality, whereas elevation of Cryab rescued animals from terminal seizures. When mice with Rosenthal fibers induced by overexpression of GFAP were crossed into a Cryab-null background, over half died at 1 month of age. Restoration of Cryab expression through the GFAP promoter reversed this outcome, showing the effect was astrocyte-specific. Conversely, in mice carrying an Alexander disease-associated mutation and in mice overexpressing wildtype GFAP, which, despite natural induction of Cryab also died at 1 month, transgenic overexpression of Cryab resulted in a markedly reduced CNS stress response, restored expression of the glutamate transporter Glt1 (SLC1A2; 600300), and protected these animals from death. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALLELIC VARIANTS (Selected Examples): | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Table View | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| .0001 MYOPATHY, MYOFIBRILLAR, ALPHA-B CRYSTALLIN-RELATED | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYAB, ARG120GLY [dbSNP:rs104894201] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In a multigeneration French family with autosomal dominant alpha-B crystallin-related myofibrillar myopathy (608810) and cataracts reported by Fardeau et al. (1978), Vicart et al. (1998) identified a heterozygous 3787A-G transition in the CRYAB gene, resulting in an arg120-to-gly (R120G) substitution. Functional expression studies in muscle cells showed that the R120G mutation resulted in the presence of cytoplasmic or perinuclear alpha-beta-crystallin-labeled aggregates in 80 to 90% of the cells. Desmin-labeled aggregates were also detected. Ultrastructural analysis showed that each aggregate had an inner dense core surrounded by 10-nm intermediate filaments that appeared to engulf the dense deposit. Fu and Liang (2003) observed that alpha-B-crystallin carrying the R120G mutation had decreased interactions with wildtype alpha-A- (123580) and alpha-B-crystallins, but slightly increased interactions with wildtype beta-B2- (123620) and gamma-C- (123680) crystallins. Chavez Zobel et al. (2003) reported that the R120G mutant protein has impaired in vivo function and structure, as reflected by a highly reduced capacity to protect cells against heat shock and by an abnormal supramolecular organization even in cells not expressing desmin. In many cells, the mutant protein accumulated in inclusion bodies that had characteristics of aggresomes concentrating around the centrosome. Three distinct chaperone mechanisms could reduce or even prevent the formation of these aggresomes: wildtype alpha-B crystallin and HSP27 (602195) prevented aggresome formation by co-oligomerizing with the R120G mutant; HSP70 (see 140550) with its cochaperone HDJ1 or CHIP (607207) reduced the frequency of aggresome formation, likely by targeting the mutant protein for degradation; and HSPB8 (608014) interacted only transiently with alpha-B but nonetheless rescued the R120G protein oligomeric organization. Chavez Zobel et al. (2003) concluded that the formation of inclusion bodies in alpha-B crystallin R120G-mediated desmin-related myopathy may be due to the misfolding of the mutant protein per se and may be delayed or prevented by expression of the wildtype alpha-B allele or other molecular chaperones, which would explain the adult onset of the disease. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| .0002 CATARACT, POSTERIOR POLAR, 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYAB, 1-BP DEL, 450A | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In a 4-generation family of English descent, Berry et al. (2001) showed that autosomal dominant posterior polar cataract (CTPP2; 613763) was caused by heterozygosity for a 1-bp deletion, 450delA, in the CRYAB gene. The deletion caused a frameshift in codon 150 and produced an aberrant protein consisting of 184 residues. Berry et al. (2001) suggested that the cataract in this family resulted from an increased tendency of the mutant polypeptide to aggregate and/or from loss of chaperone-like activity. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| .0003 MYOPATHY, MYOFIBRILLAR, ALPHA-B CRYSTALLIN-RELATED | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYAB, 2-BP DEL, 464CT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In a patient with alpha-B crystallin-related myofibrillar myopathy (608810), Selcen and Engel (2003) identified a 2-bp deletion (464delCT) in the C terminus of the CRYAB gene, resulting in a truncated protein of 162 amino acids instead of the normal 175. The mutation was predicted to impair the ability of CRYAB to inhibit heat-induced protein aggregation of unfolded and denatured proteins, resulting in aberrant accumulation of proteins in muscle fibers. Immunoblots under nondenaturing conditions showed that the mutant protein forms lower than normal molecular mass multimeric complexes with the wildtype protein and exerts a dominant-negative effect. The mutation was not found in 200 control chromosomes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| .0004 MYOPATHY, MYOFIBRILLAR, ALPHA-B CRYSTALLIN-RELATED | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYAB, GLN151TER [dbSNP:rs104894202] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In a patient with alpha-B crystallin-related myofibrillar myopathy (608810), Selcen and Engel (2003) identified a 451C-T transition in the CRYAB gene, resulting in a gln151-to-ter (Q151X) mutation. The mutation results in a truncated protein of 150 amino acids instead of the normal 175. The mutation was predicted to impair the ability of CRYAB to inhibit heat-induced protein aggregation of unfolded and denatured proteins, resulting in aberrant accumulation of proteins in muscle fibers. Immunoblots under nondenaturing conditions showed that the mutant protein forms lower than normal molecular mass multimeric complexes with the wildtype protein and exerts a dominant-negative effect. The mutation was not found in 200 control chromosomes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| .0005 MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRYAB, 1-BP DEL, 60C | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In 8 patients with fatal infantile hypertonic myofibrillar myopathy (613869), including 3 reported by Lacson et al. (1994), Del Bigio et al. (2011) identified the same homozygous 1-bp deletion in the CRYAB gene (123590.0005), resulting in a ser21-to-ala (S21A) change and a stop codon after 23 missense residues. All patients were Canadian aboriginals of Cree descent, consistent with a founder effect. The phenotype was characterized by onset in the first weeks of life of rapidly progressive muscular rigidity of the trunk and limbs associated with increasing respiratory difficulty resulting in death before age 3 years. Muscle biopsies showed dystrophic changes, endomysial fibrosis, eosinophilic deposits, and Z-band streaming. Immunohistochemistry using an antibody against the full-length CRYAB protein showed absence of staining, but an antibody against the first 10 residues of the protein showed some residual staining. Heterozygous parents were unaffected, including 1 mother with mild myopathic symptoms but normal CK levels. Del Bigio et al. (2011) noted that late-onset myofibrillar myopathy (608810) is typically seen in heterozygous individuals; however, in this disease, the parental phenotype may be rescued by limited expression of the 44-amino acid truncated nonfunctional gene product. Del Bigio et al. (2011) postulated that a disruption of CRYAB interaction with titin (TTN; 188840) may contribute to reduced muscle elasticity. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| See Also: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Quax-Jeuken et al. (1985); Rappaport et al. (1988); Vicart et al. (1996) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| REFERENCES | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||